investors.mithra.com • 1
10-08-2022 PRESS RELEASE
Regulated information
Conversion of a portion of the loans from Highbridge and Whitebox and
Information on the Total Number of Voting Rights (denominator)
Liege, Belgium, 10 August 2022 – 18:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels:
MITRA) (the "Company" or "Mithra"), a company dedicated to Women’s Health, today announces that,
following the first drawdown by the Company under the loan facility concluded with funds managed
by Highbridge Capital Management, LLC ("Highbridge") and funds managed by Whitebox Advisors, LLC
("Whitebox", and together with Highbridge, each a “Lender”), a first portion of the commitment fee due
by the Company was settled in new shares, and a first portion of the loans were contributed in kind by
the Lenders against the issuance of new shares.
On 8 August 2022, the Company and the Lenders entered into a three year term senior secured
convertible facilities agreement for an amount of up to EUR 100,000,000, which can be drawn in three
tranches. The first tranche of EUR 50,000,000 was drawn upon signing of the agreement.
Following the first drawdown, 238,337 new shares were issued at an issue price of ca. EUR 7.9401 per
share, representing 65% of the commitment fees due by the Company. Furthermore, following the
drawdown, a portion of the loans (including accrued interest, as relevant, and an option payment
amount) was contributed in kind for an aggregate amount of EUR 6,316,288.08 through the issuance
of 806,076 new shares at an issue price of ca. EUR 7.84 per share, and an aggregate amount of
EUR 1,263,418.02 through the issuance of 158,248 new shares at an issue price of ca. EUR 8.14 per
share. Following these contributions in kind, the outstanding principal amount of the loans already
drawn is EUR 43,400,000.00.
In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations
in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous
provisions, following this capital increase’s completion Mithra now has 51,781,786 outstanding shares
carrying voting rights (against 50,582,125 outstanding shares carrying voting rights previously).
Therefore, Mithra publishes the following updated information:
• Capital: EUR 37,909,225.22
• Total number of securities carrying voting rights: 51,781,786 (all ordinary shares)
• Total number of voting rights (= denominator): 51,781,786 (all relating to ordinary shares)
• Number of outstanding rights to subscribe to securities carrying voting rights:
o Pursuant to the share option plan of 5 November 2018: 1,394,900 subscription rights
giving right to 1,394,900 ordinary shares
o Pursuant to the share option plan of 22 July 2020 : 690,000 subscription rights giving
right to 690,000 ordinary shares
o Pursuant to the share option plan granted to the lending shareholders of 7 September
2020: 300,000 subscription rights giving right to 300,000 ordinary shares
o Pursuant to the share option plan of 20 November 2020: 390,717 subscription rights
giving rise to 390,717 ordinary shares.